Skip to main content
OpenTrials
Completed

NCT Number: NCT02685865

Comparison of FCSEMS and Plastic Stents

The research design is a randomized prospective clinical trial comparing Endoscopic ultrasound (EUS) guided drainage of WON using FCSEMS and plastic stents. The trial will be conducted at the Florida Hospital Center for Interventional Endoscopy, Orlando, Florida.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center for Interventional Endoscopy - Florida Hospital Orlando, Orlando, Florida, United States

Loading trial locations.

About this study

The research design is a randomized prospective clinical trial comparing EUS-guided drainage of WON using FCSEMS and plastic stents. The trial will be conducted at the Florida Hospital Center for Interventional Endoscopy, Orlando, Florida.The sample size estimated for this study is 60 patients. All patients will undergo EUS-guided drainage of WON and be randomized to either FCSEM or plastic stents in a 1:1 ratio using a computer-generated randomized sequence. It will not be possible to blind the endoscopist to the stent type being inserted due to the differences in stent appearance. The statistician will be blinded to the stent type utilized.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject (or when applicable the subject's LAR) is capable of understanding and complying with protocol requirements.
  • The subject (or when applicable the subject's LAR) is able to understand and willing to sign an informed consent form prior to the initiation of any study procedures.
  • Males or females ≥ 18 years of age.
  • WON diagnosed on contrast-enhanced dual phase CT abdomen/pelvis (CECT) or MRI with gadolinium (seen as a fluid collection in the setting of documented pancreatic necrosis that contains necrotic material and encased within a well-defined tissue layer).
  • WON of any size with any quantity of solid/necrotic component and any no. of loculations, located within the pancreatic/peri-pancreatic space not requiring percutaneous drainage, within 2cm of the enteric wall
  • Suspected/confirmed infected WON (defined as temp ≥ 100.5°F, serum White Blood Cells ≥ 15x109/L, positive blood cultures or positive Gram stain/culture of aspirated necrotic material), and/or symptomatic WON (defined as abdominal pain, gastric/intestinal/biliary outlet obstruction resulting in nausea, vomiting, early satiety, jaundice, or persistent malaise) ≥ 4 weeks from attack of acute pancreatitis.
  • Documented history of acute or chronic pancreatitis:

i. Acute pancreatitis is diagnosed if 2 of the following 3 criteria are met:

  • Abdominal pain characteristic of acute pancreatitis
  • Serum lipase/amylase ≥ x3 upper limit of normal
  • Characteristic radiological findings of acute pancreatitis on CECT/MRI/US abdomen, such as homogeneous enhancement of pancreatic parenchyma, standing of peripancreatic fat ii. Chronic pancreatitis is diagnosed if characteristic radiological changes are seen on CT/MRI with Magnetic resonance cholangiopancreatography (MRCP) (such as pancreatic atrophy, dilated pancreatic duct, pancreatic calcification) or EUS (≥5/9 of Rosement criteria)
  • Able to undergo general anesthesia

Exclusion criteria

  • Females who are pregnant or lactating. Pregnancy for females of childbearing potential will be determined by routine preoperative urine or serum Human Chorionic Gonadotropin testing.
  • Irreversible coagulopathy (INR >1.5, thrombocytopenia with platelet count <50,000/mL)
  • Has surgically altered gastrointestinal anatomy such as but not limited to Billroth II, Roux-en-Y, gastric bypass
  • Age < 18 years
  • Unable to obtain consent for the procedure from either the patient or LAR
  • Use of anticoagulants that cannot be discontinued for the procedure
  • Unable to tolerate general anesthesia
  • WON that is not accessible for EUS-guided drainage
  • Percutaneous drainage of WON is required or performed prior to EUS-guided drainage

Treatment and study plan

FCSEM Stent

Device

Hot Axios Fully covered self-expandable metal stent - Boston Scientific

Other names: Fully covered self-expandable metal stent

Plastic Stent

Device

7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific

Primary outcomes

  1. The number of interventions performed between metal and plastic stent groups to achieve treatment success

    Time frame: 6 weeks

    The primary objective of this study is to compare the number of interventions performed between metal and plastic stent groups to achieve treatment success at 6 week follow-up. Re-intervention is defined as the need for repeat EUS-guided drainage of WON using the same stent type and/or DEN and/or insertion of percutaneous catheter due to inadequate treatment response following initial WON drainage. As FCSEMS have larger diameter than plastic stents, the investigators hypothesize that the no. of re-interventions performed will be lower in the FCSEMS group compared to the plastic stent group.

Secondary outcomes

  1. Technical success

    Time frame: at index treatment Day 0

    Successful deployment of transmural stents in to the WON cavity.

  2. Treatment success

    Time frame: 6 week

    Resolution of WON on CT scan and resolution of symptoms at 6-week outpatient follow-up (from day of hospital discharge) WITHOUT the need for cross-over to minimally invasive surgical debridement

  3. Treatment failure

    Time frame: 6 months

    Need for minimally-invasive surgical debridement as a consequence of inadequate endoscopic treatment response, or death as a direct consequence of WON drainage or underlying diseaseor underlying disease.

  4. Recurrence

    Time frame: 6 months

    Development of WON or additional Pancreatic Fluid Collection and recurrence of symptoms following initial treatment success

  5. Procedure duration (minutes)

    Time frame: at index treatment Day 0

    Time from start of the procedure (endoscope inserted into the gastrointestinal lumen to perform transmural drainage to the end of the procedure (removal of the echoendoscope/ gastroscope/ duodenoscope from the oropharynx).

  6. Adverse events

    Time frame: 6 months

    Adverse event directly resulting from performing endoscopic drainage procedure. The severity will be graded according to a previously published consensus.

  7. Duration of hospitalization

    Time frame: 6 months

    Day of procedure to the day of hospital discharge

  8. Cost Analysis (Inpatient and outpatient costs)

    Time frame: 6 months

    Inpatient and outpatient costs of care will be calculated based on Medicare reimbursement fee structure.

Sponsors and collaborators

Lead sponsor

AdventHealth

Other

Registry information

Official study title

Randomized Trial Comparing Fully Covered, Self-Expanding Metal Stent and Plastic Stents for Endoscopic Ultrasound-guided Drainage of Walled-off Necrosis

Acronym: WON-MVP

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Feb 19, 2016
Registry last updated
Feb 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.